Taking biologic therapies out of the clinic

For many patients receiving biologic therapies, treatment has traditionally meant travelling to a clinic for an intravenous infusion.

But the development of large-volume autoinjectors allows more of these therapies to be self-administered at home.

Here, Meredith Bernstein, Biomedical Product Manager at mechanical testing specialist Instron, explores how increasing drug volumes are creating new considerations for device testing.

The shift towards higher-volume autoinjectors is already visible in the market. In October 2026, the US Food and Drug Administration (FDA) approved a new 2 mL autoinjector for LEO Pharma's Adbry, a biologic treatment for moderate-to-severe eczema.

Previously, patients receiving a 300 mg dose required two separate 1 mL injections. 

The new device delivers the same dose in a single injection, reducing the number of injections required.